scFv-Transferrin Fusion Protein for Crossing Biological Barriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Many antibodies face challenges in crossing biological barriers such as the blood-brain barrier and blood-eye barrier, and entering cancerous cells, reducing their efficacy and necessitating the use of their Fc region for immune responses that are not always necessary.
Innovation Solution
A single-chain variable fragment (scFv) is designed to retain antigen-binding properties without the Fc region, conjugated with the N-methyl lobe of transferrin protein to enhance transcytosis, using environment-sensitive linkers for targeted and controlled release within specific cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a whole antibody is used to bind target proteins and trigger immune responses, then immune efficacy is improved, but the ability to cross biological barriers such as blood-brain barrier and blood-eye barrier is reduced
Solution Approach 1:
The antibody is segmented into its functional components: the scFv region retains antigen-binding capability while the Fc region is removed. This segmentation allows the binding domain to function independently without the size constraints of the full antibody, enabling barrier crossing while maintaining target recognition.
Solution Approach 2:
The Fc region is extracted from the complete antibody structure, leaving only the essential antigen-binding scFv portion. This extraction removes the molecular bulk that hinders barrier penetration while preserving the therapeutic binding function, allowing the fragment to cross biological barriers that intact antibodies cannot.
2Reliability
If the Fc region is retained in the antibody structure, then immune responses such as ADCC and ADCP are enhanced, but unnecessary immune activation occurs when these responses are not required
Solution Approach 1:
The Fc region responsible for triggering immune responses is extracted from the antibody structure. This removal eliminates the mechanism for ADCC and ADCP activation, preventing unnecessary immune responses in applications where only antigen binding is desired, such as targeted delivery across biological barriers.
Solution Approach 2:
The antibody is modified to have localized functionality: the scFv region provides antigen-binding specificity while the Fc effector functions are selectively removed. This local quality adjustment allows the molecule to perform binding functions without activating immune responses, matching the functional requirements of specific therapeutic applications.
3Length of moving object
If conjugation with transferrin protein is used to enhance transcytosis, then delivery across biological barriers is improved, but molecular complexity increases
Solution Approach 1:
The scFv antigen-binding fragment is merged with the transferrin protein through genetic fusion. This combining creates a single polypeptide chain that integrates the barrier-crossing capability of transferrin with the target-specific binding of scFv, achieving enhanced transcytosis without requiring separate conjugation steps or complex assembly.
Solution Approach 2:
The fusion protein achieves multiple functions in a single molecule: transferrin provides the transcytosis mechanism for crossing biological barriers, while the attached scFv provides antigen-specific binding. This multi-functionality eliminates the need for separate delivery and binding components, simplifying the overall system despite the increased molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The scFv-conjugate achieves enhanced delivery across biological barriers, improves selectivity, reduces off-target effects, and prolongs circulation time, ensuring effective therapeutic action in target tissues.
Implementation Method 1
conjugated with the N-methyl lobe of transferrin protein to enhance transcytosis
Data Source
AI summary
The efficacy and indication of teprotumumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.